Comment on

• Cyclo-oxygenase-2 inhibitors and cardiovascular events.

  Warner TD, Mitchell JA, Vane JR. Warner TD, et al. Lancet. 2002 Nov 23;360(9346):1700-1. doi: 10.1016/S0140-6736(02)11635-7. Lancet. 2002. PMID: 12457830 No abstract available.
• Vioxx, the implosion of Merck, and aftershocks at the FDA.

  Horton R. Horton R. Lancet. 2004 Dec 4-10;364(9450):1995-6. doi: 10.1016/S0140-6736(04)17523-5. Lancet. 2004. PMID: 15582041 No abstract available.
• Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

  Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Jüni P, et al. Lancet. 2004 Dec 4-10;364(9450):2021-9. doi: 10.1016/S0140-6736(04)17514-4. Lancet. 2004. PMID: 15582059